BR9811137A - Processo para redução de hiperglicemia e processo para redução de hiperglicemia e estabilização do nìvel de glicose sérica, composição farmacêutica, e, uso de tripicolinato crÈmico sintético - Google Patents

Processo para redução de hiperglicemia e processo para redução de hiperglicemia e estabilização do nìvel de glicose sérica, composição farmacêutica, e, uso de tripicolinato crÈmico sintético

Info

Publication number
BR9811137A
BR9811137A BR9811137-0A BR9811137A BR9811137A BR 9811137 A BR9811137 A BR 9811137A BR 9811137 A BR9811137 A BR 9811137A BR 9811137 A BR9811137 A BR 9811137A
Authority
BR
Brazil
Prior art keywords
reducing hyperglycemia
tripicolinate
synthetic
pharmaceutical composition
glucose level
Prior art date
Application number
BR9811137-0A
Other languages
English (en)
Inventor
Mark F Mccarty
Original Assignee
Nutrition 21
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26808096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9811137(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/908,819 external-priority patent/US5789401A/en
Application filed by Nutrition 21 filed Critical Nutrition 21
Publication of BR9811137A publication Critical patent/BR9811137A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

"PROCESSO PARA REDUçãO DE HIPERGLICEMIA E ESTABILIZAçãO DO NìVEL DE GLICOSE SéRICA, COMPOSIçãO FARMACêUTICA, E, USO DE TRIPICOLINATO CRÈMICO SINTéTICO"<D>. Um processo para tratamento de diabetes de tipo II pela administração a um indivíduo não afetado de uma combinação de tripicolinato crómico e biotina. Os dois compostos são administrados oral ou parenteralmente em doses diárias que proporcionam entre 50 e 1.000 Ág de cromo e entre 25 Ág e 200 mg de biotina, as quantidades de cromo e biotina sendo selecionadas juntas para proporcionar um efeito mais do que aditivo.
BR9811137-0A 1997-08-08 1998-07-31 Processo para redução de hiperglicemia e processo para redução de hiperglicemia e estabilização do nìvel de glicose sérica, composição farmacêutica, e, uso de tripicolinato crÈmico sintético BR9811137A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/908,819 US5789401A (en) 1997-08-08 1997-08-08 High-dose chromium/biotin treatment of type II diabetes
US09/110,511 US5929066A (en) 1997-08-08 1998-07-06 Chromium/biotin treatment of Type II diabetes
PCT/US1998/016103 WO1999007387A1 (en) 1997-08-08 1998-07-31 Chromium/biotin treatment of type ii diabetes

Publications (1)

Publication Number Publication Date
BR9811137A true BR9811137A (pt) 2000-07-18

Family

ID=26808096

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811137-0A BR9811137A (pt) 1997-08-08 1998-07-31 Processo para redução de hiperglicemia e processo para redução de hiperglicemia e estabilização do nìvel de glicose sérica, composição farmacêutica, e, uso de tripicolinato crÈmico sintético

Country Status (14)

Country Link
US (1) USRE39480E1 (pt)
EP (1) EP1001793B1 (pt)
JP (1) JP2001513506A (pt)
CN (1) CN1273531A (pt)
AT (1) ATE304364T1 (pt)
AU (1) AU751431B2 (pt)
BR (1) BR9811137A (pt)
CA (1) CA2297834C (pt)
CZ (1) CZ298680B6 (pt)
DE (1) DE69831576T2 (pt)
ES (1) ES2251097T3 (pt)
HU (1) HUP0003713A2 (pt)
IL (1) IL134163A0 (pt)
WO (1) WO1999007387A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
ES2251097T3 (es) 1997-08-08 2006-04-16 Nutrition 21 Tratamiento con cromo/biotina de la diabetes tipo ii.
US6376549B1 (en) 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
EP1113804A2 (en) 1998-09-17 2001-07-11 Akesis Pharmaceuticals, Inc. Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
CN1512887A (zh) * 2001-02-27 2004-07-14 21 铬/生物素治疗血脂异常和饮食诱发的饭后高血糖症
US20050214384A1 (en) * 2002-04-23 2005-09-29 Vijaya Juturu Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
JP2004043443A (ja) * 2002-05-14 2004-02-12 Kumamoto Technology & Industry Foundation アミロイドーシスの予防及び治療のための医薬
CN100457122C (zh) * 2002-05-14 2009-02-04 尼普洛株式会社 包含三价铬离子的化合物在制备用于预防和/或治疗淀粉样变性的药物的应用
JP2004203863A (ja) * 2002-12-09 2004-07-22 Taisho Pharmaceut Co Ltd 抗糖尿病用組成物
CN1320925C (zh) * 2005-03-30 2007-06-13 淮北市辉克药业有限公司 长期使用的治疗糖尿病的复方制剂
CA3021932C (en) * 2007-01-31 2020-12-15 Jds Therapeutics, Llc Use of chromium histidinate for treatment of cardiometabolic disorders
PL2134351T3 (pl) 2007-03-13 2017-10-31 Jds Therapeutics Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
JP6152346B2 (ja) 2011-03-01 2017-06-21 ジェーディーエス セラピューティックス、エルエルシーＪＤＳ Ｔｈｅｒａｐｅｕｔｉｃｓ，ＬＬＣ 糖尿病、低血糖、および関連障害の治療および予防のためのインスリンとクロムの組成物
ES2395529B1 (es) 2011-06-08 2014-04-11 Pri, S.A. Combinación sinérgica para el tratamiento de la diabetes mellitus tipo 2.
CN102488220A (zh) * 2011-11-28 2012-06-13 中哈福生物医药科技（上海）有限公司 降血糖组合物，其制备方法及具有降血糖功能的保健食品
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
US10820617B1 (en) 2018-03-29 2020-11-03 Government Of The United States, As Represented By The Secretary Of The Air Force All inclusive electrolytes, vitamins, and protein powder training supplement

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US6140304A (en) 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
JPH05505935A (ja) * 1990-02-05 1993-09-02 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ビタミン，ミネラルおよび他の有利な補給剤の徐放性処方
US5336672A (en) * 1992-07-21 1994-08-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Increasing egg production in poultry
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US5744161A (en) * 1995-02-24 1998-04-28 Sabinsa Corporation Use of piperine as a bioavailability enhancer
US6329361B1 (en) * 1995-05-12 2001-12-11 Nutrition 21 High-dose chromic picolinate treatment of type II diabetes
US5597585A (en) * 1995-12-26 1997-01-28 Williams; Andrew H. Vitamin/mineral composition
US5635535A (en) * 1996-04-05 1997-06-03 Wagstaff; Robert K. Method for increasing blood glucose levels
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
ES2251097T3 (es) 1997-08-08 2006-04-16 Nutrition 21 Tratamiento con cromo/biotina de la diabetes tipo ii.
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6365176B1 (en) 2000-08-08 2002-04-02 Functional Foods, Inc. Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy

Also Published As

Publication number Publication date
DE69831576T2 (de) 2006-06-14
CZ2000324A3 (cs) 2001-03-14
EP1001793B1 (en) 2005-09-14
EP1001793A1 (en) 2000-05-24
HUP0003713A2 (hu) 2001-04-28
ATE304364T1 (de) 2005-09-15
JP2001513506A (ja) 2001-09-04
CN1273531A (zh) 2000-11-15
IL134163A0 (en) 2001-04-30
WO1999007387A1 (en) 1999-02-18
USRE39480E1 (en) 2007-01-23
CA2297834A1 (en) 1999-02-18
CA2297834C (en) 2008-09-30
AU8765198A (en) 1999-03-01
ES2251097T3 (es) 2006-04-16
AU751431B2 (en) 2002-08-15
CZ298680B6 (cs) 2007-12-19
DE69831576D1 (de) 2005-10-20

Similar Documents

Publication Publication Date Title
BR9811137A (pt) Processo para redução de hiperglicemia e processo para redução de hiperglicemia e estabilização do nìvel de glicose sérica, composição farmacêutica, e, uso de tripicolinato crÈmico sintético
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
KR920019347A (ko) 당뇨병의 치료방법
KR910004185A (ko) 세포독소 약제에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그 사용
KR930003912A (ko) 울혈성 심장 마비 치료법
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR9811249A (pt) Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
BR9813826A (pt) Potencial de uso abusivo de administração oral de opióide analgésico
BR0202375A (pt) Composições farmacêutica compreendendo drogas e polìmeros de aumento da concentração
EP1576956A3 (en) Chromium/biotin treatment of type II diabetes
KR870006891A (ko) 구강 위생 조성물
BR0110837A (pt) Quimioterapia de combinação
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BR0008011A (pt) Agente embranquecedor fluorescente, suapreparação e uso
KR970025615A (ko) 암 전이 억제제
TR199701294T1 (xx) Amoksisilin ve klavulanik asitten olu�an terkip.
BR0011928A (pt) Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética
KR900005978A (ko) 키니딘, 아르테미시닌 및 이의 유도체를 사용한 항말라리아 조성물 및 치료방법
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
KR890014107A (ko) 백금 화학 요법약제
BR0013625A (pt) Composição para uso no tratamento de carcinoma hepatocelular
KR920017669A (ko) 갈륨 화합물
BR0101492A (pt) Misturas de pelo menos um enchedor e compostosde organossilìcio, processo para sua preparação eseu uso

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO, DE ACORDO COM O ARTIGO 8O DA LPI